Page 186 - 2018_10-Haematologica-web

1752
haematologica | 2018; 103(10)
M. Rijkers et al.
Transfusion. 2009;49(9):1825–1835.
6. Middelburg RA, Porcelijn L, Lardy N, Briët E, Vrielink H. Prevalence of leucocyte antibod- ies in the Dutch donor population. Vox Sang. 2011;100(3):327-335.
7. Rebulla P. A mini-review on platelet refrac- toriness. Haematologica. 2005;90(2):247- 253.
8. Doughty H, Murphy M, Metcalfe P, et al. Relative importance of immune and non- immune causes of platelet refractoriness. Vox Sang. 1994;66(3):200-205.
9. Saris A, Tomson B, Brand A, et al. Platelets from donors with consistent low HLA-B8, B12 or B35 expression do not undergo anti- body-mediated internalization. Blood. 2018;131(1):144-152.
10. Jackman RP, Deng X, Bolgiano D, et al. Low- level HLA antibodies do not predict platelet transfusion failure in TRAP study partici- pants. Blood. 2013;121(16):3261-3267.
11. Jia Y, Li W, Liu N, et al. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients. Transfus Med. 2014; 26(6):406-410.
12. Messerschmidt G, Makuch R, Appelbaum F, et al. A prospective randomized trial of HLA-matched versus mismatched single- donor platelet transfusions in cancer patients. Cancer. 1988;62(4):795-801.
13. Zeng Q, Zhu L, Tao L, et al. Relative efficacy of steroid therapy in immune thrombocy- topenia mediated by anti-platelet GPIIbIIIa versus GPIba antibodies. Am J Hematol. 2011;87(2):206-208.
14. Peng J, Ma S, Liu J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014;12(4):497-504.
15. Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoim- mune thrombocytopenic purpura: their clin- ical significance and response to treatment. Blood. 1993;81(5):1246-1250.
16. LiJ,vanderWalDE,ZhuG,etal. Desialylation is a mechanism of Fc-indepen- dent platelet clearance and a therapeutic tar- get in immune thrombocytopenia. Nat Commun. 2015;6:7737.
class I molecules and Fc receptor. Blood.
1992;79(11):2901-2908.
20. Brandt J, Julius C, Osborne J, Anderson C.
The mechanism of platelet aggregation induced by HLA-related antibodies. Thromb Haemost. 1996;76(5):774-779.
21. Mulder A, Eijsink C, Kardol MJ, et al. Identification, isolation, and culture of HLA- A2-specific B lymphocytes using MHC class I tetramers. J Immunol. 2003;171(12):6599- 6603.
22. Mulder A, Kardol M, Regan J, Buelow R, Claas F. Reactivity of twenty-two cytotoxic human monoclonal HLA antibodies towards soluble HLA class I in an enzyme- linked immunosorbent assay (PRA- STAT). Hum Immunol. 1997;56(1-2):106-113.
23. Nightingale MJ, Ceulemans J, Ágoston S, et al. The value to blood establishments of sup- plier quality audit and of adopting a European Blood Alliance collaborative approach. Blood Transfus. 2014;12(1):91-98.
24. Rijkers M, van der Meer PF, Bontekoe IJ, et al. Evaluation of the role of the GPIb-IX-V receptor complex in development of the platelet storage lesion. Vox Sang. 2016;111(3):247-256.
25. Mulder A, Eijsink C, Kester MGD, et al. Impact of peptides on the recognition of HLA class I molecules by human HLA anti- bodies. J Immunol. 2005;175(9):5950–5957.
26. Maynard DM, Heijnen HFG, Horne MK, White JG, Gahl WA. Proteomic analysis of platelet alpha-granules using mass spec- trometry. J Thromb Haemost. 2007;5(9): 1945-1955.
27. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glyco- protein IIb- IIIa complex during platelet acti- vation. J Biol Chem. 1985;260(20):11107- 11114.
28. Qiao J, Al-Tamimi M, Baker RI, Andrews RK, Gardiner EE. The platelet Fc receptor, FcγRIIa. Immunol Rev. 2015;268(1):241- 252.
29. Arman M, Krauel K. Human platelet IgG Fc receptor FcγRIIA in immunity and throm- bosis. J Thromb Haemost. 2015;13(6):893– 908.
30. Yamamoto N, Takeshita K, Shichijo M, et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imida- zo[1,2-c]pyrimidin-5-ylamino]-nicotinamide dihydrochloride (BAY 61-3606) blocks anti- gen- induced airway inflammation in rodents. J Pharmacol Exp Ther. 2003;306(3): 1174-1181.
31. Yanaga F, Poole A, Asselin J, et al. Syk inter- acts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fcγ-llA receptor.
Biochem J. 1995;311(Pt2):471-478.
32. Rubinstein E, Boucheix C, Urso I, Carroll RC. Fc gamma receptor-mediated inter- platelet activation by a monoclonal antibody against beta 2 microglobulin. J Immunol.
1991;147(9):3040-3046.
33. Daga S, Moyse H, Briggs D, et al. Direct
quantitative measurement of the kinetics of HLA-specific antibody interactions with iso- lated HLA proteins. Hum Immunol. 2018;79(2):122-128.
34. Duquesnoy RJ, Marrari M, Jelenik L, et al. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocyto- toxicity assays. Hum Immunol. 2013;74(10): 1271-1279.
35. Taylor SM, Reilly MP, Schreiber AD, et al. Thrombosis and shock induced by activat- ing antiplatelet antibodies in human FcγRIIA transgenic mice: the interplay among anti- body, spleen, and Fc receptor. Blood. 2000;96(13):4254-4260.
36. Kretschmer V, Huss B, Feller K, Ponath N, Kiefel V. Influence of HPA-1a and HLA antibodies on primary hemostasis. Semin Thromb Hemost. 1995;21(suppl 2):96-102.
37. Waterman HR, Kapp LM, Munday A, Odem-Davis K, Zimring JC. Transfusion- induced alloimmunization and platelet refractoriness in a mouse model: mecha- nisms and interventions. Transfusion. 2016;56(1):91-100.
38. Valenzuela NM, Mulder A, Reed EF. HLA class I antibodies trigger increased adher- ence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcγRs. J Immunol. 2013;190(12):6635-6650.
39. Jones CG, Pechauer SM, Curtis BR, et al. IgG in normal plasma inhibits HIT antibody- mediated platelet activation: implications for plasma exchange in HIT. Blood. 2018;131(3):703-706.
40. Padmanabhan A, Jones CG, Pechauer SM, et al. IVIg for treatment of severe refractory heparin-induced thrombocytopenia. Chest. 2017;152(3):478-485.
41. Quach ME, Dragovich MA, Chen W, et al. Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets. Blood. 2018;15(131):787-796.
42. Hoffmeister KM, Falet H. Platelet clearance by the hepatic Ashwell-Morrell receptor: mechanisms and biological significance. Thromb Res. 2016;141 Suppl 2:S68-S72.
43. Duquesnoy R, Marrari M, Mulder A, et al. First report on the antibody verification of HLA-ABC epitopes recorded in the website- based HLA Epitope Registry. Tissue Antigens. 2014;83(6):391-400.
17. Arepally GM. Heparin-induced thrombocy- topenia. Blood. 2017;129(21):2864-2872.
18. Rollin J, Pouplard C, Sung HC, et al.
Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. Blood. 2015;125(15):2397-2404.
19. Rubinstein BE, Urso I, Boucheix C, Carroll RC. Platelet activation by cross-linking HLA